ArticleBMC gastroenterology2025
Screening for metabolic-associated fatty liver disease in type 2 diabetes patients using non-invasive scores and ultrasound: a cross-sectional study in Egypt.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.Annals of medicine · 2026Article
- Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?World journal of nephrology · 2026Article
- Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan.World journal of gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMAFLD is very common among T2DM patients and contributes significantly to both liver and systemic complications. This study aimed to evaluate the reliability of non-invasive scores and abdominal ultrasound for diagnosing and screening MAFLD in Egyptian T2DM patients.
methodsA cross-sectional study was conducted on 300 patients with T2DM who attended the Diabetes Outpatient Clinic at Benha Teaching Hospital. Liver enzymes, non-invasive fibrosis (FIB-4 and NFS), and steatosis (HSI and FLI) indices were evaluated alongside abdominal ultrasonography. Patients were stratified into two groups based on MAFLD diagnosis and assessed for disease presence and severity predictors using logistic regression models.
resultsMAFLD prevalence was 46.33%. FIB-4 with an AUC of 0.826 (95% CI:0.778-0.875)and NFS with an AUC of 0.964 (95% CI:0.942-0.986) demonstrated high diagnostic accuracy for fibrosis, while HSI with an AUC of 0.847 (95% CI:0.803-0.890) and FLI with an AUC of 0.835 (95% CI:0.789-0.881) effectively identified hepatic steatosis. The HSI (38.31 ± 6.93) and FLI (68.78 ± 29.98) placed patients in the high probability category for liver steatosis, while the FIB-4 (1.94 ± 0.81) and NFS (0.56 ± 1.24) scores indicated moderate fibrosis risk. Ultrasound findings corroborated these results, with 80.58% of patients presenting with mild to moderate steatosis. Higher BMI, increased waist circumference, elevated liver function markers (elevated ALT, AST, GGT, and albumin), higher lipid profile, and poor glycemic control (HbA1c) were key predictors of MAFLD.
conclusionsNon-invasive indices alongside ultrasound support screening efforts to detect MAFLD in T2DM patients early, offering opportunities for timely management and prevention of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.